Kenvue Inc. (KVUE) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the fiscal quarter ended June 29, 2025. Kenvue Inc. is a global consumer health company operating through three segments: Self Care, Skin Health and Beauty, and Essential Health. The company is currently undergoing a strategic review of alternatives initiated by the Board in July 2025 and is in the process of relocating to a new global headquarters in Summit, New Jersey.
Key Financial Metrics
| Metric | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Net Sales | $3,839M | $4,000M | $7,580M | $7,894M |
| Gross Profit | $2,261M | $2,365M | $4,429M | $4,607M |
| Operating Income | $692M | $154M | $1,250M | $704M |
| Net Income | $420M | $58M | $742M | $354M |
| Diluted EPS | $0.22 | $0.03 | $0.39 | $0.18 |
| Operating Cash Flow (YTD) | $1,049M | $727M | - | - |
| Total Debt | $8,610M | - | - | - |
| Cash & Equivalents | $1,070M | - | - | - |
Note: Q2 2024 results were significantly impacted by $510M in impairment charges, primarily related to the Dr.Ci:Labo brand.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 4.0% year-over-year in Q2. Organic sales declined 4.2%, driven by a 3.3% volume decrease (softer allergy/sun seasons, trade inventory fluctuations) and 0.9% unfavorable value realization (strategic price investments).
- Profitability Improvement: Operating income surged to $692M from $154M in Q2 2024. This increase is largely attributable to the absence of the $510M impairment charge recorded in the prior year.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased 8.3% due to lower separation-related costs ($50M reduction) and savings from the "Our Vue Forward" restructuring initiative.
- Restructuring Costs: Restructuring expenses increased to $60M in Q2 2025 from $48M in Q2 2024, driven by higher information technology and project-related costs.
Guidance, Outlook, and Risks
- Strategic Review: The Board has established a Strategic Review Committee to evaluate alternatives, including optimizing the brand portfolio, to unlock value. No specific transaction is guaranteed.
- Restructuring Outlook: The "2024 Multi-Year Restructuring Initiative" targets approximately $550M in total pre-tax charges. The company expects to realize full annualized pre-tax gross cost savings of ~$350M beginning in fiscal year 2026.
- Tariff Exposure: Management estimates an incremental gross tariff exposure of approximately $150M annualized due to new U.S. trade policies and retaliatory measures.
- Legal Contingencies: Significant litigation risks remain regarding talc-related liabilities (outside U.S./Canada), acetaminophen (autism/ADHD claims), phenylephrine (effectiveness claims), and benzoyl peroxide (benzene content). The company states it cannot reasonably estimate the magnitude of potential liability for many of these matters.
- Dividends: The Board declared a quarterly dividend of $0.2075 per share, a 1.2% increase, payable in August 2025.
Investor Verification Checklist
- Organic Sales Drivers: Verify the sustainability of volume declines in Self Care (allergy/cough) and Skin Health (sun) segments versus seasonal normalization.
- Restructuring Execution: Monitor the pace of the "Our Vue Forward" initiative to ensure the projected $350M in annualized savings are realized by 2026.
- Strategic Review Outcome: Assess the timeline and potential impact of the Board's strategic review on the company's brand portfolio and capital structure.
- Legal Accruals: Review Note 13 for updates on talc, acetaminophen, and phenylephrine litigation, specifically regarding the ability to estimate potential losses.
- Tariff Mitigation: Evaluate management's actions to offset the estimated $150M annualized tariff exposure.